VCEL Stock Analysis: Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a huma
- Latest close
- $40.15
- 20-day change
- +0.00%
- Trend state
- NEUTRAL
- Classification
- Healthcare · Biotechnology
Market context
Vericel Corporation moved +0.00% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.
Latest report
The latest cached company filing period (FY2025 · $276.3M revenue · $16.5M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 5.8/6, while Value is the lowest at 3.1/6. Scores are comparative research signals, not forecasts.